-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
Recently, Antikang Biotechnology announced that the company's independent research and development of the company's independent research and development of the new drug ADC189 for the treatment and prevention of influenza A and B has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
Screenshot source: CDE official website
It is reported that ADC189 has a new anti-influenza mechanism that can directly inhibit virus replication
Antikang Bio's design and development of ADC189 aims to combat influenza A and B viruses, including influenza strains resistant to oseltamivir and avian influenza strains (H7N9, H5N1)
It is worth mentioning that a single oral dose of this new drug under development can block influenza virus replication within 24 hours
Public information shows that the Antikang bioscientist team has long focused on the research and development of small molecule innovative drugs in the field of anti-infection
According to Dr.
Reference materials:
[1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.